Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States

Affiliations

¹ Columbia University Irving Medical Center New York, New York.
² University of Texas Health Science Center at Houston Houston, Texas.
³ Vanderbilt University Medical Center Nashville, Tennessee.
⁴ Veterans Affairs Medical Center Nashville, Tennessee.
⁵ Georgetown University Medical Center Washington, District of Columbia.
⁶ Northwestern University Chicago, Illinois.
⁷ Stanford University and Palo Alto VA Health Care System Palo Alto, California.
⁸ University of Pennsylvania Philadelphia, Pennsylvania.
⁹ University of Utah Salt Lake City, Utah.
¹⁰ Hospital for Special Surgery New York City, New York.
¹¹ University of Michigan Ann Arbor, Michigan.
¹² Duke University Durham, North Carolina.
¹³ University of Minnesota Minneapolis, Minnesota.
¹⁴ Scleroderma Research Foundation San Francisco, California.
¹⁵ Massachusetts General Hospital Boston, Massachusetts.
¹⁶ University of California, Los Angeles Los Angeles, California.
¹⁷ Medical University of South Carolina Charleston, South Carolina.
¹⁸ Mayo Clinic Rochester, Minnesota.
¹⁹ Johns Hopkins University Baltimore, Maryland.

Yiming Luo et al. Ann Am Thorac Soc. 2025 Aug.

. 2025 Aug;22(8):1265-1269.

doi: 10.1513/AnnalsATS.202410-1045RL.

¹ Columbia University Irving Medical Center New York, New York.
² University of Texas Health Science Center at Houston Houston, Texas.
³ Vanderbilt University Medical Center Nashville, Tennessee.
⁴ Veterans Affairs Medical Center Nashville, Tennessee.
⁵ Georgetown University Medical Center Washington, District of Columbia.
⁶ Northwestern University Chicago, Illinois.
⁷ Stanford University and Palo Alto VA Health Care System Palo Alto, California.
⁸ University of Pennsylvania Philadelphia, Pennsylvania.
⁹ University of Utah Salt Lake City, Utah.
¹⁰ Hospital for Special Surgery New York City, New York.
¹¹ University of Michigan Ann Arbor, Michigan.
¹² Duke University Durham, North Carolina.
¹³ University of Minnesota Minneapolis, Minnesota.
¹⁴ Scleroderma Research Foundation San Francisco, California.
¹⁵ Massachusetts General Hospital Boston, Massachusetts.
¹⁶ University of California, Los Angeles Los Angeles, California.
¹⁷ Medical University of South Carolina Charleston, South Carolina.
¹⁸ Mayo Clinic Rochester, Minnesota.
¹⁹ Johns Hopkins University Baltimore, Maryland.

No abstract available

References

1. Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev . 2015;24:411–419. - PMC - PubMed
1. Washington, DC: Food and Drug Administration; 2019. FDA approves first treatment for patients with rare type of lung disease.https://www.fda.gov/news-events/press-announcements/fda-approves-first-t...
1. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. INBUILD Trial Investigators Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med . 2019;381:1718–1727. - PubMed
1. Khanna D, Lescoat A, Roofeh D, Bernstein EJ, Kazerooni EA, Roth MD, et al. Systemic sclerosis-associated interstitial lung disease: how to incorporate two Food and Drug Administration-approved therapies in clinical practice. Arthritis Rheumatol . 2022;74:13–27. - PMC - PubMed
1. Shankar DA, Hawkins F, Alysandratos KD, Wilson KC, Walkey AJ, Bosch NA, et al. Uptake of antifibrotics for patients with idiopathic pulmonary fibrosis: 2016–2022. Ann Am Thorac Soc . 2024;21:170–173. - PMC - PubMed